AXIA Pharmaceutical is voluntarily recalling all unused sterile drug products within expiry due to a lack of assurance of sterility. The recalled sterile products have been found to be inconsistent with federal gui...
Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, shares his thoughts on closing gaps in cannabinoid research to make progress in pain m...
The U.S. Food and Drug Administration is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk facto...
The following report was submitted by Robert Wailes, MD, AAPM AMA Delegate The Interim Meeting of the American Medical Association (AMA) House of Delegates (HOD) convened November 16, 2019 in San Diego. I represented the...
AAPM joined nine other medical specialty societies in writing to the Oregon Health Authority urging prerequisite training for the performance of spine interventions.
AAPM joined efforts with nine other societies to share comments with the National Government Services Inc. regarding its recently published Future Local Coverage Determinations for Percutaneous Vertebral Augmentation for...
The Interagency Pain Research Coordinating Committee will hold its next meeting on November 18, 2019, and will be available on a videocast. For more information.
U.S. Senator Susan Collins (R-ME), the Chairman of the Aging Committee, and Senator Tina Smith (D-MN) introduced the Mitigating Emergency Drug Shortages (MEDS) Act, legislation that would help increase the supplies of vi...
This commentary responds to a case and examines pragmatic concerns about operating a busy outpatient practice in compliance with new laws that regulate opioid prescribing. Specifically, the article considers how regulati...
The Drug Enforcement Administration announced proposed regulations to improve DEA's ability to oversee the production of dangerous drugs at the height of the national opioid crisis. This proposed regulation would further...